Shares of Ra Pharmctl Inc (NASDAQ:RARX) have been assigned an average recommendation of “Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $24.00.

Several analysts have recently weighed in on RARX shares. Zacks Investment Research upgraded Ra Pharmctl from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th. Jefferies Group LLC restated a “buy” rating and issued a $25.00 price objective on shares of Ra Pharmctl in a report on Thursday, September 28th. Finally, Royal Bank Of Canada initiated coverage on Ra Pharmctl in a report on Thursday, September 14th. They issued an “outperform” rating and a $21.00 price objective for the company.

Ra Pharmctl (NASDAQ:RARX) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.06).

COPYRIGHT VIOLATION WARNING: “Ra Pharmctl Inc (RARX) Given Consensus Recommendation of “Buy” by Analysts” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/ra-pharmctl-inc-rarx-given-consensus-recommendation-of-buy-by-analysts/1674851.html.

Hedge funds and other institutional investors have recently made changes to their positions in the company. American International Group Inc. purchased a new stake in shares of Ra Pharmctl during the first quarter valued at $102,000. TIAA CREF Investment Management LLC lifted its holdings in shares of Ra Pharmctl by 97.0% during the first quarter. TIAA CREF Investment Management LLC now owns 7,837 shares of the company’s stock valued at $167,000 after purchasing an additional 3,859 shares during the last quarter. Alliancebernstein L.P. purchased a new stake in shares of Ra Pharmctl during the second quarter valued at $195,000. Wells Fargo & Company MN lifted its holdings in shares of Ra Pharmctl by 151.8% during the first quarter. Wells Fargo & Company MN now owns 9,455 shares of the company’s stock valued at $202,000 after purchasing an additional 5,700 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Ra Pharmctl by 30.6% during the second quarter. The Manufacturers Life Insurance Company now owns 10,860 shares of the company’s stock valued at $204,000 after purchasing an additional 2,543 shares during the last quarter. 66.80% of the stock is owned by institutional investors and hedge funds.

About Ra Pharmctl

Ra Pharmaceuticals, Inc is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutics for diseases of complement dysregulation and a range of orphan indications. It utilizes small molecules and peptide approaches to address pathological targets in the complement cascade.

Analyst Recommendations for Ra Pharmctl (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmctl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmctl Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.